Literature DB >> 16315224

Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug.

David J Waterhouse1, Joseph E Saavedra, Keith M Davies, Michael L Citro, Xia Xu, Douglas A Powell, George J Grimes, Gopal K Potti, Larry K Keefer.   

Abstract

PROLI/NO is an agent of structure XN(O)==NONa (X = L-prolyl) whose 2-s half-life for nitric oxide (NO) release at physiological pH makes it an excellent prodrug for localizing NO's therapeutic effects at the site of application, but a difficult one to formulate and certify as pure. Despite its extraordinary thermal and hydrolytic instability, however, PROLI/NO could be formulated as an injectable drug by dissolving it in cold 0.1 M sodium hydroxide containing 5% D-mannitol, then quickly ultrafiltering and lyophilizing it in evacuated septum vials. No evidence for decomposition was seen in the contents of these evacuated vials when stored at -20 degrees C over a 140-day observation period, as judged by quantifying NO release in simulated infusate solutions (10 mM carbonate/bicarbonate, pH 10.5). The only hydrolysis products detected were NO, nitrite ion, proline, and N-nitrosoproline, all products of normal human physiological processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16315224     DOI: 10.1002/jps.20486

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Michael M Goodblatt; Vidya Udupi; Swati Malaviya; Paul J Shami; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

2.  Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas.

Authors:  Astrid Weyerbrock; Stuart Walbridge; Joseph E Saavedra; Larry K Keefer; Edward H Oldfield
Journal:  Neuro Oncol       Date:  2010-11-01       Impact factor: 12.300

3.  Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: requirement for Cyp1a1.

Authors:  Wei Qu; Lida Cheng; Anna L Dill; Joseph E Saavedra; Sam Y Hong; Larry K Keefer; Michael P Waalkes
Journal:  Chem Biol Interact       Date:  2011-05-20       Impact factor: 5.192

4.  Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status.

Authors:  Melissa E Hogg; Vinit N Varu; Ashley K Vavra; Daniel A Popowich; Monisha N Banerjee; Janet Martinez; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe
Journal:  Free Radic Biol Med       Date:  2011-01-21       Impact factor: 7.376

5.  Water-soluble poly(ethylenimine)-based nitric oxide donors: preparation, characterization, and potential application in hemodialysis.

Authors:  Zhengrong Zhou; Gail M Annich; Yiduo Wu; Mark E Meyerhoff
Journal:  Biomacromolecules       Date:  2006-09       Impact factor: 6.988

6.  Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Anna E Maciag; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  Org Lett       Date:  2008-10-29       Impact factor: 6.005

7.  Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome.

Authors:  Sadaf S Ahanchi; Vinit N Varu; Nick D Tsihlis; Janet Martinez; Charles G Pearce; Muneera R Kapadia; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Joseph A Hrabie; Melina R Kibbe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-17       Impact factor: 4.733

8.  Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia.

Authors:  Charles G Pearce; Samer F Najjar; Muneera R Kapadia; Jozef Murar; Jason Eng; Brian Lyle; Oliver O Aalami; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe
Journal:  Free Radic Biol Med       Date:  2007-09-25       Impact factor: 7.376

9.  V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity.

Authors:  Wei Qu; Jie Liu; Anna L Dill; Joseph E Saavedra; Larry K Keefer; Michael P Waalkes
Journal:  Cancer Sci       Date:  2008-12-15       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.